Citations

Showing 10 of 108083 citations.

Clinical Characteristics of Ocular Sarcoidosis: A Population-Based Study 1976–2013
Ungprasert, Patompong , Tooley, Andrea A. , Crowson, Cynthia S. , Matteson, Eric L. , Smith, Wendy M.

Mayo Clinic

Ocular Immunology and Inflammation | October 12, 2017 | Volume: 27 | Issue: 3 | Pages: 389-395

10.1080/09273948.2017.1386791 | PMID 29023165 Get It

Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica
Schaller, K , Owens, Gregory P. , Cotleur, Anne C. , Kellner, Debra , Takeshita, Yukio , Obermeier, Birgit , Kryzer, Thomas J., Sano, Yasuteru , Kanda, Takashi , Lennon, Vanda A. , Ransohoff, Richard M. , Bennett, Jeffrey L. , Shimizu, Fumitaka , Schaller, Kristin L , Kellner, Debra , Obermeier, Birgit , Sano, Yasuteru , Kanda, Takashi , Ransohoff, Richard M , Bennett, Jeffrey L , Shimizu, Fumitaka , Cotleur, Anne C

Mayo Clinic

Science Translational Medicine | October 12, 2017 | Volume: 9 | Issue: 397 | Pages: No page available

10.1126/scitranslmed.aai9111 | PMID 28679661 Get It

An autoantibody target on brain microvascular endothelial cells in patients with neuromyelitis optica may be exploited to manipulate blood-brain barrier permeability.
Radioembolization for hepatocellular carcinoma: The time has come
Toskich, Beau B. , Patel, Tushar

Mayo Clinic

Hepatology | October 12, 2017 | Volume: 67 | Issue: 3 | Pages: 820-822

10.1002/hep.29590 | PMID 29023925 Get It

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)
Moriarty, James P. , Dusetzina, Stacie B. , Himelstein, Andrew L., Foster, Jared C. , Grubbs, Stephen S., Novotny, Paul J. , Shapiro, Charles L. , Dusetzina, Stacie, Borah, Bijan J. , Dusetzina, Stacie

Mayo Clinic

Journal of Clinical Oncology | October 12, 2017 | Volume: 35 | Issue: 35 | Pages: 3949-3955

10.1200/jco.2017.73.7437 | PMID 29023215 Get It

Purpose Skeletal-related events (SREs) such as pathologic fracture, spinal cord compression, or the necessity for radiation or surgery to bone metastasis cause considerable morbidity, decrements in quality of life, and costs to the health care system. The results of a recent large randomized trial (Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology [CALGB/Alliance 70604]) showed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs. We sought to determine the cost-effectiveness (CE) of monthly ZA, ZA every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases. Methods Using a Markov model, costs per SRE avoided were calculated for the three treatments. Sensitivity analyses were performed where denosumab SRE probabilities were assumed to be 50%, 75%, and 90% lower than the ZA SRE probabilities. Quality-adjusted life-years were also calculated. The analysis was from the US payer perspective. Results The mean costs of the denosumab treatment strategy are nine-fold higher than generic ZA every 3 months. Quality-adjusted life-years were virtually identical in all the three treatment arms; hence, the optimal treatment would be ZA every 3 months because it was the least costly treatment. The sensitivity analyses showed that relative to ZA every 3 months, the incremental costs per mean SRE avoided for denosumab ranged from $162,918 to $347,655. Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab. This analysis was one of the first to incorporate the costs of generic ZA and one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively. ZA every 3 months is the more CE option and more reasonable alternative to monthly denosumab.
Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention
Scharf, Eugene

Mayo Clinic

Cannabis & Cannabinoid Research | October 12, 2017 | Volume: 2 | Issue: 1 | Pages: 259-264

10.1089/can.2017.0033 | PMID 29098188 Get It

Abstract Introduction: The endocannabinoid system (ECS) regulates functions throughout human physiology, including neuropsychiatric, cardiovascular, autonomic, metabolic, and inflammatory states. The complex cellular interactions regulated by the ECS suggest a potential for vascular disease and stroke prevention by augmenting central nervous and immune cell endocannabinoid signaling. Discussion: The endocannabinoid N-arachidonoylethanolamine (anandamide) plays a central role in augmenting these processes in cerebrovascular and neurometabolic disease. Furthermore, cannabidiol (CBD), a nonpsychoactive constituent of Cannabis , is an immediate therapeutic candidate both for potentiating endocannabinoid signaling and for acting at multiple pharmacological targets. Conclusion: This speculative synthesis explores the current state of knowledge of the ECS and suggests CBD as a therapeutic candidate for stroke prevention by exerting favorable augmentation of the homeostatic effects of the ECS and, in turn, improving the metabolic syndrome, while simultaneously stalling the development of atherosclerosis.
Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
Musso, Carla , Major, Maria Laura, Andrés, Eugenia de, Simha, Vinaya , Major, María Laura, Andres, Eugenia

Mayo Clinic

Clinical Medicine Insights: Case Reports | October 12, 2017 | Volume: 9 | Issue: No issue available | Pages: No page available

10.4137/ccrep.s40196 | PMID 28096701 Get It

Generalized lipodystrophy (GL) is a rare inherited or acquired disease characterized by widespread loss of subcutaneous fat, leading to leptin deficiency, ectopic fat deposition, and severe metabolic abnormalities. Previous studies have shown the benefit of leptin replacement (metreleptin) in ameliorating metabolic complications, but little is known about the experience of metreleptin treatment outside of a research setting. We report on post-marketing clinical experience with metreleptin therapy in three patients with GL and marked hypoleptinemia, uncontrolled diabetes, and hypertriglyceridemia. After metreleptin treatment for 12–168 weeks, the mean glycated hemoglobin decreased from 10.9% to 5.8%, and serum triglycerides were normalized (a mean decline of 90%). These benefits were observed within weeks of starting therapy, were durable, and were accompanied by subjective improvements in quality of life, decreased need for concomitant medications, and no significant adverse effects. Metreleptin was safe and effective in normalizing certain severe metabolic abnormalities in the clinic setting.
Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort
Dungan, Kathleen , Craven, Timothy E. , Soe, Kyaw , Wright, Jackson T. , Basile, Jan , Haley, William E. , Kressin, Nancy R. , Rani, Uzma , Tamariz, Leonardo , Whittle, Jeff , Wiggers, Alan , Osei, Kwame

Mayo Clinic

Diabetes, Obesity and Metabolism | October 12, 2017 | Volume: 20 | Issue: 3 | Pages: 629-637

10.1111/dom.13127 | PMID 29024310 Get It

Aims To determine whether baseline metabolic syndrome (MetS) modifies the effect of intensive blood pressure control on cardiovascular (CV) outcomes, and whether the effects varied by race/ethnicity. Methods We performed post hoc analyses among non‐Hispanic black, non‐hispanic white and Hispanic participants, with and without MetS, in the Systolic Blood Pressure Intervention Trial (SPRINT), who were randomized to a systolic blood pressure (SBP) target of <120 mm Hg (intensive group, N = 4544) or an SBP target of <140 mm Hg (standard group, N = 4553). The median follow‐up was 3.26 years. The primary outcome was the composite of the first occurrence of myocardial infarction, stroke, heart failure, non‐myocardial infarction acute coronary syndrome or CV death. Results Overall, 3521/9097 participants (38.7%) met the criteria for MetS at baseline. Baseline characteristics were similar in the two SBP target groups within each MetS subgroup, except body mass index was slightly higher in the standard arm of the MetS subgroup (33.3 ± 5.6 vs 33.0 ± 5.3 kg/m 2 ; P < .01), but were similar across treatment arms in the non‐MetS subgroup. The hazard ratio for the primary outcome was similarly reduced in participants with or without baseline MetS: 0.75 (95% confidence interval [CI] 0.57, 0.96) and 0.71 (95% CI 0.57, 0.87), respectively (adjusted P value for treatment by subgroup interaction = .98). Similarly, there was no evidence of treatment × MetS subgroup interaction for all‐cause mortality (adjusted interaction P value = .98). The findings were also similar across race/ethnic subgroups. Conclusions In this analysis the CV benefit of intensive SBP control did not differ among participants by baseline MetS status, regardless of race/ethnicity.
Alcohol consumption, variability in alcohol dehydrogenase genes and risk of renal cell carcinoma
Antwi, Samuel O. , Eckel‐Passow, Jeanette E. , Diehl, Nancy D., Serie, Daniel, Custer, Kaitlynn, Wu, Kevin J. , Cheville, John C. , Thiel, David D. , Leibovich, Bradley C. , Parker, Alexander S. , Antwi, Samuel O

Mayo Clinic

International Journal of Cancer | October 12, 2017 | Volume: 142 | Issue: 4 | Pages: 747-756

10.1002/ijc.31103 | PMID 29023769 Get It

Alcohol consumption has been associated inversely with renal cell carcinoma (RCC) risk; however, no study has examined effect modification by germline variation in alcohol‐metabolizing genes. We investigated whether the association between alcohol intake and RCC risk is modulated by germline variants in alcohol dehydrogenase genes in a large case–control study. Data from 652 RCC cases and 1,366 non‐cancer controls were analyzed. Alcohol intake was assessed using a standardized risk factor questionnaire. Three previously genotyped polymorphisms in ADH6 and ADH7 with the TaqMan assay were examined. Odds ratios (ORs) and 95% confidence interval (CI) were calculated using logistic regression, adjusting for covariates. Compared to non‐drinkers, ever consumption of alcohol was associated with lower RCC risk (OR = 0.52, 95% CI = 0.42–0.65). Analysis with cubic spline regression curve showed a “J‐shaped” relationship between alcohol drinks/day and RCC risk, such that there was no added benefit against RCC for consumption of more than two drinks/day. We observed effect modification by variation in rs1154454 (ADH7) (pinteraction = 0.007); a per unit increase in alcohol drink/day was associated with 35% lower RCC risk among non‐minor allele carriers, a 27% lower risk among those who carry one copy of the minor allele, but no association was observed among those with two copies of the minor allele. These findings indicate that alcohol consumption is associated with lower RCC risk. Consuming more than two drinks a day does not confer additional protection against RCC. The association between alcohol intake and RCC risk appears to be modulated by inter‐individual germline variation in alcohol‐metabolizing genes.
Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults
Wilke, Christopher , Grosshans, David R. , Duman, Joseph G. , Brown, Paul D. , Grosshans, David, Duman, Joseph, Li, Jing

Mayo Clinic

Neuro-Oncology | October 12, 2017 | Volume: 20 | Issue: 5 | Pages: 597-607

10.1093/neuonc/nox195 | PMID 29045710 Get It